{
  "docId": "019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "docSlug": "8f301a1a54ee099c965687c909e40052",
  "documentTitle": "Equillium | Investor Presentation Deck | 40 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 40,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a combination of qualitative physician sentiment and quantitative survey data to frame the problem of safety in current standard-of-care treatments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-cd1b-731e-ae5e-e1dc823ccd70/25",
  "deckHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "deckJsonHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70.json",
  "deckAnchorHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.925,
        "x": 0.037,
        "y": 0.00188
      },
      "kind": "callout",
      "text": "EQ101 is positioned as a well-tolerated and effective alternative to JAK inhibitors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c24c53b-aa36-403a-ab34-5ec41dd49efd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.18,
        "x": 0.51,
        "y": 0.0057
      },
      "kind": "chart",
      "text": "Donut chart showing 66% Agree, 21% Neutral, 13% Disagree",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da40db21-4987-4d86-8fa4-48a634352f81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.16,
        "x": 0.037,
        "y": 0.0076
      },
      "kind": "metric",
      "text": "79%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0adc41f5-3293-4580-943b-f8f1180cde37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.22,
        "x": 0.2,
        "y": 0.0079
      },
      "kind": "paragraph",
      "text": "of physicians surveyed, believe there is an extremely high unmet medical need*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "066b71f9-44e4-4892-ada8-4efe540240c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.39,
        "x": 0.037,
        "y": 0.0034500000000000004
      },
      "kind": "paragraph",
      "text": "Currently approved and late-stage pipeline drugs are all JAK inhibitors. There remains a chronic need, without a safe chronic treatment. Dermatologists indicate safety concerns are the primary barriers to JAKi use in AA patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "738a6322-a31f-4d64-81fd-2d04af470ae7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.49,
        "y": 0.0034500000000000004
      },
      "kind": "quote",
      "text": "I am concerned about the safety of oral JAK inhibitors for my AA patients",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "310194de-88ce-467a-8e22-b17cab784a14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.12,
        "y": 0.0096
      },
      "kind": "source-note",
      "text": "* Spherix Global Insights, 2022; ** Olumiant Package Insert",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "456e810d-6e18-4e8c-be4d-4ad0141c085b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.23,
        "x": 0.73,
        "y": 0.0034500000000000004
      },
      "kind": "table",
      "text": "Blackbox warning details for JAK inhibitors",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86d0cf7a-f976-4239-86e3-5bbad14d8044",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.435,
        "x": 0.037,
        "y": 0.075
      },
      "kind": "title",
      "text": "Large Unmet Need in Alopecia Areata",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bd1f453-0dec-495a-9d01-eaca8a054018",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "cee82080-6497-4cca-936e-c7795a93685e",
      "evidence": "The slide presents a problem (large unmet need in alopecia areata), agitates it (safety concerns with current treatments), and hints at a solution (EQ101 as an alternative).",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "problem-solution-fit",
      "slug": null,
      "matchId": "b1078f03-1d5d-4859-91fa-69757cf0b970",
      "evidence": "Contrasts current safety issues with the proposed alternative EQ101",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a49a5aeb-65c4-48dc-8f1c-9f7651ff1fb1",
      "evidence": "The loop is visible in the problem statement on page 25",
      "position": 0,
      "objective": "What is the cost of not treating alopecia areata?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}